Sedona Invest has acquired Abiocom
The shareholders of Abiocom have sold the company to Sedona Invest.
Sedona Invest is a family office founded in 2020 dedicated to the well-being and organic industries.
Founded in 2007, Abiocom is specialized in design, development and distribution of organic well-being products. The company provides a wide range of more than 300 products from seven own brands and two other brands in exclusive distribution, covering five categories: food supplements, cosmetics, make-up, incense and eco-housing. Abiocom has a portfolio of over 1,700 active clients, including organic chains and independent stores.
Oaklins’ team in France acted as advisor to the shareholders of Sedona Invest in this transaction.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more